Mereo BioPharma Group (MREO) Analyst Estimates Annual - Discounting Cash Flows
Mereo BioPharma Group plc
MREO (NASDAQ)

* (except for per share items) of USD
Period Ending: 2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
2021
12-31
Number of Analysts 1 3 4 5 4 2 1
Estimated Revenue
Low 111 49.0 33.4 17.0 14.5 6.79 18.4
Average 111 49.0 33.6 17.0 14.5 6.79 18.4
High 111 49.0 33.9 17.0 14.5 6.79 18.4
Estimated EBITDA
Low -47.5 -20.9 -14.5 -7.25 -6.19 -2.90 -9.42
Average -47.5 -20.9 -14.4 -7.25 -6.19 -2.90 -9.42
High -47.5 -20.9 -14.3 -7.25 -6.19 -2.90 -9.42
Estimated EBIT
Low -48.1 -21.2 -14.7 -7.33 -6.26 -2.93 -9.51
Average -48.1 -21.2 -14.5 -7.33 -6.26 -2.93 -9.51
High -48.1 -21.2 -14.4 -7.33 -6.26 -2.93 -9.51
Estimated Net Income
Low 34.5 -31.9 -17.3 -37.2 -70.0 -23.1 -30.9
Average 34.5 9.23 -17.3 -27.4 -33.9 -21.2 -30.9
High 34.5 41.9 -17.3 5.32 70.0 -19.2 -30.9
Estimated SGA Expenses
Low -1,360 -599 -415 -207 -177 -83.0 -225
Average -1,360 -599 -411 -207 -177 -83.0 -225
High -1,360 -599 -408 -207 -177 -83.0 -225
Estimated EPS
Low 0.052 -0.048 -0.026 -0.056 -0.106 -0.035 -0.047
Average 0.052 -0.008 -0.026 -0.032 -0.035 -0.035 -0.047
High 0.052 0.063 -0.026 0.008 0.106 -0.029 -0.047
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us